Morphology and etiopathogenesis of the abdominal aortic aneurysm
Authors:
Lada Eberlová 1,2; Zbyněk Tonar 1; Věra Křížková 1; Jitka Kočová 1; Marie Korabečná 3; Vladislav Třeška 4; Jiří Moláček 4; Karel Houdek 4; Ludmila Boudová 5; Ondřej Topolčan 6; Jindra Vrzalová 6; Martin Pešta 6; Vlastimil Kulda 7; Lukáš Nedorost 1; Jiří Valenta 2
Authors‘ workplace:
Ústav histologie a embryologie Lékařské fakulty UK, Plzeň
1; Ústav anatomie Lékařské fakulty UK, Plzeň
2; Ústav biologie Lékařské fakulty UK, Plzeň
3; Chirurgická klinika FN, Plzeň
4; Šiklův ústav patologie FN, Plzeň
5; Centrální laboratoř pro imunoanalýzu, 2. interní klinika FN, Plzeň
6; Ústav lékařské chemie a biochemie Lékařské fakulty UK, Plzeň
7
Published in:
Čas. Lék. čes. 2012; 151: 55-63
Category:
Review Article
Overview
The paper summarizes the latest research on the abdominal aorta aneurysm etiopathogenesis and compares normal aorta morphology with changes in the aortic aneurysm wall. The role of risk factors, especially hemodynamic and genetic, is discussed in detail. Special attention is paid to inflammatory processes including cytokines and matrix degrading proteases that contribute to the development of aneurysm. The role of thrombus and the current results of research into biomarkers indicating the risks and progression of the disease are analysed. Finally, a review of pharmacomodulation of the aortic aneurysm using statins, antibiotics, antihypertensive and nonsteroidal antiinflammatory drugs is presented.
Key words:
abdominal aortic aneurysm, histology, etiopathogenesis, biomarkers, pharmacomodulation. Eb.
Sources
1. Gillum RF. Epidemiology of aortic aneurysm in the United States. J Clin Epidemiol 1995; 48: 1289–1298.
2. Eickhoff JH. Incidence of diagnosis, operation and death from abdominal aortic aneurysms in Danish hospitals: results from a nation-wide survey, 1977–1990. Eur J Surg 1993; 159: 619–623.
3. Vardulaki KA, et al. Incidence among men of asymptomatic abdominal aortic aneurysms: estimates from 500 screen detected cases. J Med Screen 1999; 6: 50–54.
4. Powell JT, Brady AR. Detection, management, and prospects for the medical treatment of small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004; 24: 241–245.
5. Cowan JA Jr, et al. Epidemiology of aortic aneurysm repair in the United States from 1993 to 2003. Ann N Y Acad Sci 2006; 1085: 1–10.
6. Lederle FA, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 2002; 287: 2968–2972.
7. Bengtsson H, Bergqvist D. Ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg 1993; 18: 74–80.
8. Heikkinen M, et al. Ruptured abdominal aortic aneurysm in a well-defined geographic area. J Vasc Surg 2002; 36: 291–296.
9. Mealy K, Salman A. The true incidence of ruptured abdominal aortic aneurysms. Eur J Vasc Surg 1988; 2: 405–408.
10. Kantonen I, et al. Mortality in ruptured abdominal aortic aneurysms. The Finnvasc Study Group. Eur J Vasc Endovasc Surg 1999; 17: 208–212.
11. Darling RC, et al. Autopsy study of unoperated abdominal aortic aneurysms. The case for early resection. Circulation 1977; 56: II161–164.
12. Kent KC, et al. Screening for abdominal aortic aneurysm: a consensus statement. J Vasc Surg 2004; 39: 267–269.
13. Šebesta P. Břišní aorta a pánevní tepny. In: Krajíček M, et al. Chirurgická a intervenční léčba cévních onemocnění. Praha: Grada Publishing 2007; 192.
14. Třeška V, et al. Aneuryzma břišní aorty. Praha: Grada Publishing 1999.
15. Wolinsky H, Glagov S. Structural Basis for the Static Mechanical Properties of the Aortic Media. Circ Res 1964; 14: 400–413.
16. Dingemans KP, et al. Extracellular Matrix of the Human Aortic media: An Ultrastructural Histochemical and Immunohistochemical Study of the Adult Aortic Media. Anat Rec 2000; 258: 1–14.
17. Stintzing S, et al. Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis. Virchows Arch 2009; 455: 171–185.
18. Shanahan CM, Weissberg PL. Smooth muscle cell phenotypes in atherosclerotic lesions. Curr Opin Lipidol 1999; 10: 507–513.
19. Grabenwöger M, et al. Endothelialization of biosynthetic vascular prostheses after laser perforation. Ann Thorac Surg 1998; 66: 110–114.
20. Stary HC. Natural History and Histological Classification of Atherosclerotic Lesions. An Update. Arterioscler Tromb Vasc Biol 2000; 20: 1177–1178.
21. Stary HC. Slide atlas of atherosclerosis: Progression and regression. CD-ROM. New York: Parthenon Publishing 2002.
22. Virmani R, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262–1275.
23. Tonar Z, et al. Kvantitativní popis aterosklerotických lézí na úrovni optické mikroskopie. Cor Vasa 2007; 49: 95–101.
24. Kočová J. Overall staining of connective tissue and the muscular layer of vessels. Folia Morphologica 1970; 18: 293–295.
25. Koch AE, et al. Human Abdominal Aortic Aneurysms Immunophenotypic Analysis Suggesting an Immune-mediated Response. American Journal of Pathology 1990; 137: 1199–1213.
26. Třeška V, et al. Inflammation in the wall of abdominal aortic aneurysm and its role in the symptomatology of aneurysm. Cytokines, Cellular & Molecular Therapy 2002; 7: 91–97.
27. Tonar Z, et al. Stereological tools for quantitative microscopy of the aortic wall with focus on the abdominal aortic aneurysm (2010). In: Méndez-Vilas A, Díaz J (Eds.). Microscopy: Science, Technology, Applications and Education. Applications in Biology and Medicine. Vol. 2. Formatex Research Centre, Badajoz, 926–935.
28. Holmes DR, et al. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg 1995; 21: 761–771.
29. Choke E, et al. A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 2005; 30: 227–244.
30. Dalman RL. Oxidative stress and abdominal aneurysms: how aortic hemodynamic conditions may influence AAA disease. Cardiovasc Surg 2003; 11: 417–419.
31. Buschmann I, Schaper W. Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News in Physiological Sciences 1999; 14: 121–125.
32. Harter LP, et al. Ultrasonic evaluation of abdominal aortic thrombus. J Ultrasound Med 1982; 1: 315–318.
33. Falk E. Dynamics in thrombus formation. Ann N Y Acad Sci 1992; 667: 205–223.
34. Touat Z, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 2006; 168: 1022–1030.
35. Adolph R, et al. Cellular content and permeability of intraluminal thrombus in abdominal aortic aneurysm. J Vasc Surg 1997; 25: 916–926.
36. Tilson MD, Seashore MR. Human genetics of the abdominal aortic aneurysm. Surg Gynecol Obstet 1984; 158: 129–132.
37. Johansen K, Koepsell T. Familial tendency for abdominal aortic aneurysms. JAMA 1986; 256: 1934–1936.
38. Baird PA, et al. Sibling risks of abdominal aortic aneurysm. Lancet 1995; 346: 601–604.
39. Vardulaki KA, et al. Quantifying the risk of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. Br J Surg 2000; 87: 195–200.
40. Brady AR, et al. Abdominal Aortic Aneurysm Expansion: Risk Factors and Time Intervals for Surveillance. Circulation 2004; 110: 16–21.
41. Blanchard JF, et al. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: The TromsŅ Study. Am J Epidemiol 2001; 154: 236–244.
42. Choke E, et al. Review of Biological Factors Implicated in Abdominal Aortic Aneurysm Rupture. Eur J Vasc Endovasc Surg 2005; 30: 227–244.
43. Thompson A, et al. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010; 52: 55–61.
44. LaMorte WW, et al. Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: relationship to cardiovascular risk factors. J Vasc Surg 1995; 21: 422–431.
45. Humphrey JD, Taylor CA. Intracranial and abdominal aortic aneurysms: similarities, differences, and need for a new class of computational models. Annu Rev Biomed Eng 2008; 10: 221–246.
46. Nichols KB, Rodriguez AA. Comparison of and investigation into the size effects on the rotational dynamics of two spherical molecules: CCl4 and C60. J Phys Chem A 2005; 109: 3009–3014.
47. Clifton MA. Familial abdominal aortic aneurysms. Br J Surg 1977; 64: 765–766.
48. Salo JA, et al. Familial occurrence of abdominal aortic aneurysm. Ann Intern Med 1999; 130: 637–642.
49. Baird PA, et al. Sibling risks of abdominal aortic aneurysm. Lancet 1995; 346: 601–604.
50. Tilson MD, Seashore MR. Fifty families with abdominal aortic aneurysms in two or more first-order relatives. Am J Surg 1984; 147: 551–553.
51. Majumder PP, et al. On the inheritance of abdominal aortic aneurysm. Am J Hum Genet 1991; 48: 164–170.
52. Kuivaniemi H, et al. Familial abdominal aortic aneurysms: collection of 233 multiplex families. J Vasc Surg 2003; 37: 340–345.
53. Pola R, et al. Abdominal aortic aneurysm in normotensive patients: association with angiotensin-converting enzyme gene polymorphism. Eur J Vasc Endovasc Surg 2001; 21: 445–449.
54. Jones K, et al. The influence of 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene promoter on the incidence, growth and operative risk of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2002; 23: 421–425.
55. Strauss E, et al. Increased risk of the abdominal aortic aneurysm in carriers of the MTHFR 677T allele. J Appl Genet 2003; 44: 85–93.
56. Fatini C, et al. eNOS G894T polymorphism as a mild predisposing factor for abdominal aortic aneurysm. J Vasc Surg 2005; 42: 415–419.
57. Rasmussen TE, et al. Human leukocyte antigen class II immune response genes, female gender, and cigarette smoking as risk and modulating factors in abdominal aortic aneurysms. J Vasc Surg 2002; 35: 988–993.
58. Sandford RM, et al. The genetic basis of abdominal aortic aneurysms: a review. Eur J Vasc Endovasc Surg 2007; 33: 381–390.
59. Gregory AK, et al. Features of autoimmunity in the abdominal aortic aneurysm. Arch Surg 1996; 131: 85–88.
60. Tambiah J, et al. Provocation of experimental aortic inflammation and dilatation by inflammatory mediators and Chlamydia pneumoniae. Br J Surg 2001; 88: 935–940.
61. Hance KA, et al. Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg 2002; 35: 254–261.
62. Bown MJ, et al. The role of cytokine gene polymorphisms in the pathogenesis of abdominal aortic aneurysms: a case-control study. J Vasc Surg 2003; 37: 999–1005.
63. Juvonen J, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1997; 17: 2843–2847.
64. Dawson J, et al. Circulating cytokines in patients with abdominal aortic aneurysms. Ann N Y Acad Sci 2006; 1085: 324–326.
65. Rohde LE, et al. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler Thromb Vasc Biol 1999; 19: 1695–1699.
66. Houard X, et al. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res 2009; 82: 532–541.
67. Middleton RK, et al. Characterisation of Interleukin-8 and monocyte chemoattractant protein-1 expression within the abdominal aortic aneurysm and their association with mural inflammation. Eur J Vasc Endovasc Surg 2009; 37: 46–55.
68. Třeška V, et al. Cytokines as plasma markers of abdominal aortic aneurysm. Clin Chem Lab Med 2000; 38: 1161–1164.
69. Davis VA, et al. Cytokine pattern in patients with abdominal aortic aneurysm. Vasc Endovascular Surg 2011; 45: 63–68.
70. Muehling BM, et al. In vivo study on the expression pattern of resistin in patients with abdominal aortic aneurysm. Vasc Endovascular Surg 2011; 45: 63–68.
71. Pan JH, et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. J Vasc Surg 2003; 37: 628–635.
72. Loftus IM, Thompson MM. The role of matrix metalloproteinases in vascular disease. Vasc Med 2002; 7: 117–133.
73. Jones GT, et al. Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. J Vasc Surg 2003; 38: 1363–1367.
74. Eriksson P, et al. Genotype-phenotype relationships in an investigation of the role of proteases in abdominal aortic aneurysm expansion. Br J Surg 2005; 92: 1372–1376.
75. Irizarry E, et al. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 1993; 54: 571–574.
76. Knox JB, et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997; 95: 205–212.
77. Davis V, et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1998; 18: 1625–1633.
78. Crowther M, et al. Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. J Vasc Surg 2000; 32: 575–583.
79. Erdozain OJ, et al. Hypoxia in abdominal aortic aneurysm supports a role for HIF-1α and Ets-1 as drivers of matrix metalloproteinase upregulation in human aortic smooth muscle cells. J Vasc Res 2011; 48: 163–170.
80. Elmore JR, et al. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann Vasc Surg 1998; 12: 221–228.
81. Fontaine V, et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161: 1701–1710.
82. Thompson RW, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995; 96: 318–326.
83. Mao D, et al. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun 1999; 261: 904–910.
84. Tamarina NA, et al. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta.Surgery. 1997; 122: 264–271.
85. Elmore JR, et al. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann Vasc Surg 1998; 12: 221–228.
86. Defawe OD, et al. TIMP-2 and PAI-1 mRNA levels are lower in aneurysmal as compared to athero-occlusive abdominal aortas. Cardiovasc Res 2003; 60: 205–213.
87. Wilson WR, et al. Plasma matrix metalloproteinase levels do not predict tissue levels in abdominal aortic aneurysms suitable for elective repair. Vascular 2008; 16: 248–252.
88. Hovsepian DM, et al. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000; 11: 1345–1352.
89. Eugster T, et al. Aminoterminal propeptide of type III procollagen and matrix metalloproteinases-2 and -9 failed to serve as serum markers for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2005; 29: 378–382.
90. Lindholt JS, et al. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg 2000; 20: 281–285.
91. Abdul-Hussien H, et al. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol 2007; 170: 809–817.
92. Abdul-Hussien H, et al. The pathophysiology of abdominal aortic aneurysm growth: corresponding and discordant inflammatory and proteolytic processes in abdominal aortic and popliteal artery aneurysms. J Vasc Surg 2010; 51: 1479–1487.
93. Shi GP, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191–1197.
94. Lindholt JS, et al. Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg 2001; 88: 1472–1475.
95. Lindholt JS, et al. Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes. J Vasc Surg 2001; 34: 611–615.
96. Lindholt JS, et al. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 25: 546–551.
97. Lindholt JS. Activators of plasminogen and the progression of small abdominal aortic aneurysms. Ann N Y Acad Sci 2006; 1085: 139–150.
98. Kríková V, et al. Quantification of plasminogen activator inhibitor type 1 in the aortic wall. Int Angiol 2009; 28: 44–49.
99. Lindholt JS, et al. Systemic levels of cotinine and elastase, but not pulmonary function, are associated with the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 26: 418–422.
100. Molacek J, et al. Optimization of the model of abdominal aortic aneurysm-experiment in an animal model. J Vasc Res 2009; 46: 1–5.
101. Kazi M, et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg 2003; 38: 1283–1292.
102. Sakalihasan N, et al. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 1996; 24: 127–133.
103. Fontaine V, et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161: 1701–1710.
104. Wolf YG, et al. Computed tomography scanning findings associated with rapid expansion of abdominal aortic aneurysms. J Vasc Surg. 1994; 20: 529–535.
105. Stenbaek J, et al. Growth of Thrombus may be a Better Predictor of Rupture than Diameter in Patients with Abdominal Aortic Aneurysms. Eur J Vasc Endovasc Surg 2000; 20: 466–469.
106. Hans SS, et al. Size and location of thrombus in intact and ruptured abdominal aortic aneurysms. J Vasc Surg 2005; 41: 584–588.
107. Lindholt JS, et al. A review of Chlamydia pneumoniae and atherosclerosis. Eur J Vasc Endovasc Surg 1999; 17: 283–289.
108. Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31: 453–463.
109. Lindholt JS, et al. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J Vasc Surg 2001; 34: 212–215.
110. Lindholt JS, et al. Vascular surgical society of great britain and ireland: immunoglobulin A antibodies against chlamydia pneumoniae are associated with expansion of small abdominal aortic aneurysms and declining ankle blood pressure. Br J Surg 1999; 86: 698.
111. Falkensammer B, et al. Lack of microbial DNA in tissue specimens of patients with abdominal aortic aneurysms and positive Chlamydiales serology. Eur J Clin Microbiol Infect Dis 2007; 26: 141–145.
112. Becker RC. Emerging paradigms, platforms, and unifying themes in biomarker science. J Am Coll Cardiol 2007; 50: 1777–1780.
113. Urbonavicius S, et al. Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture-a systematic review. Eur J Vasc Endovasc Surg 2008; 36: 273–280.
114. Lindholt JS, et al. Serum-elastin-peptides as a predictor of expansion of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1997; 14: 12–16.
115. Lindholt JS, et al. Serum elastin peptides in the preoperative evaluation of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001; 22: 546–550.
116. Satta J, et al. Aminoterminal propeptide of type III procollagen in the follow-up of patients with abdominal aortic aneurysms. J Vasc Surg 1997; 25: 909–915.
117. Treska V, Topolcan O. Plasma and tissue levels of collagen types I and III markers in patients with abdominal aortic aneurysms. Int Angiol 2000; 19: 64–68.
118. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants Lancet 1998; 352: 1649–1655.
119. Filipovic M, et al. Elective surgery for aortic abdominal aneurysm: comparison of English outcomes with those elsewhere. J Epidemiol Community Health 2007; 61: 226–231.
120. McCarthy RJ, et al. Recommendations for screening intervals for small aortic aneurysms. Br J Surg 2003; 90: 821–826.
121. Cooper DG, et al. Role of medical intervention in slowing the growth of small abdominal aortic aneurysms. Postgrad Med J 2009; 85: 688–692.
122. Linhart A, et al. Angiologie. In: Češka R. et al. Interna. Praha: Triton 2010; 189–190.
123. Ricci MA, et al. Effects of hypertension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model. Ann N Y Acad Sci 1996; 800: 89–96.
124. Liao S, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33: 1057–1064.
125. Biancari F, et al. Ten-year outcome of patients with very small abdominal aortic aneurysm. Am J Surg 2002; 183: 53–55.
126. Hackam DG, et al. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006; 368: 659–665.
127. Wilson WR, et al. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005; 30: 259–262.
128. Steinmetz EF, et al.. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241: 92–101.
129. Schouten O, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32: 21–26.
130. Mosorin M, et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg 2008; 7: 578–581.
131. Petrinec D, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23: 336–346.
132. Vammen S, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001; 88: 1066–1072.
133. Franklin IJ, et al. Vascular surgical society of great britain and ireland: non-steroidal anti-inflammatory drugs to treat abdominal aortic aneurysm. Br J Surg 1999; 86: 707.
134. Thompson SG, et al. Multicentre Aneurysm Screening Study Group. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ 2009; 338: b2307.
135. Schmidt T, et al. Benefit, risks and cost-effectiveness of screening for abdominal aortic aneurysm. Rofo 2010; 182: 573–580.
136. Lindholt JS, et al. Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ 2005; 330: 750.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
![Issue 2](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/ed4fb8f1acb40e6d0cc52cb16c4d4982.jpeg)
Most read in this issue
- Prevalence of thrombophilic mutations of FV Leiden, prothrombin G20210A and PAI-1 4G/5G and their combinations in a group of 1,450 healthy middle-aged individuals in the Prague and Central Bohemian regions (results of FRET real-time PCR assay)
- Relapsing polychondritis
- Male hypogonadism and civilization diseases
- Morphology and etiopathogenesis of the abdominal aortic aneurysm